Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
62,337,402
-
Total 13F shares
-
39,972,031
-
Share change
-
-6,413,763
-
Total reported value
-
$22,485,572
-
Put/Call ratio
-
3316%
-
Price per share
-
$0.56
-
Number of holders
-
70
-
Value change
-
-$3,751,363
-
Number of buys
-
35
-
Number of sells
-
24
Institutional Holders of Elevation Oncology, Inc. - Common Stock, par value $0.0001 per share (ELEV) as of Q4 2024
As of 31 Dec 2024,
Elevation Oncology, Inc. - Common Stock, par value $0.0001 per share (ELEV) was held by
70 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
39,972,031 shares.
The largest 10 holders included
Frazier Life Sciences Management, L.P., TANG CAPITAL MANAGEMENT LLC, FARALLON CAPITAL MANAGEMENT LLC, BlackRock, Inc., BVF INC/IL, Aisling Capital Management LP, VANGUARD GROUP INC, GOLDMAN SACHS GROUP INC, RENAISSANCE TECHNOLOGIES LLC, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
70
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.